INO Slips On Clinical Hold, MRK Gets FDA Nod, Be All Ears For AKAO

Achaogen Inc. (AKAO) is scheduled to present data from Cohort 2 of phase III clinical trial of Plazomicin in patients with serious bacterial infections due to carbapenem-resistant enterobacteriaceae on Saturday, October 29, 2016.

from RTT - Biotech http://ift.tt/2dRyZwP
via IFTTT